title: Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer.
abstract: OBJECTIVE
  This study was conducted to investigate the association of vasculogenic mimicry (VM) formation and CD133 expression with the clinical outcomes of patients with ovarian cancer.
  
  
  METHODS
  This retrospective study was performed in 120 ovarian carcinoma samples. VM formation and CD133 expression was identified with CD31/periodic acid-Schiff double-staining and CD133 immunohistochemical staining. Collected clinical and pathological data included age at diagnosis, histologic type, tumor grade, tumor stage, lymph node metastases and response to chemotherapy. The overall survival time was calculated.
  
  
  RESULTS
  VM was identified in 52 (43%) of 120 ovarian carcinoma tissues and CD133 expression was found in 56 (47%) cases. Both VM formation and CD133 expression were associated with advanced tumor stage, high-grade carcinoma and non-response to chemotherapy (p < 0.05). They were also associated with shorter overall survival time (p < 0.05) by log-rank test. Combined marker of VM formation and CD133 expression was associated with high-grade ovarian carcinoma, late-stage disease, non-response to chemotherapy and shorter overall survival time (p < 0.05).
  
  
  CONCLUSIONS
  VM formation and CD133 expression can provide additional prognostic information for patients with ovarian cancer. Combined marker of VM formation and CD133 expression may be a potent predictor for poor prognosis for patients with ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Hebei Medical University, Hebei, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Liang
authors.forename: Bo
authors.initials: B
authors.lastname: Yang
authors.forename: Qinying
authors.initials: Q
authors.lastname: Cao
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Wu
mesh_terms: D000071916:AC133 Antigen / Q000096:biosynthesis*; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000378:metabolism* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D000071916:AC133 Antigen; C000606023:PROM1 protein, human